Stockscreener 앱 받기
21.92
3.79%
0.80
시간 외 거래:
21.92
전일 마감가:
$21.12
열려 있는:
$21.04
하루 거래량:
1.01M
Relative Volume:
0.75
시가총액:
$1.98B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-10.01
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
-0.41%
1개월 성능:
+3.30%
6개월 성능:
-12.88%
1년 성능:
-34.99%
1일 변동 폭
$20.96
$22.27
1주일 범위
$20.50
$22.86
52주 변동 폭
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
21.92 | 1.98B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World
Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World
Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by California State Teachers Retirement System - Defense World
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - Longview News-Journal
IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys 10,543 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
January 2026 Options Now Available For IDEAYA Biosciences - Nasdaq
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha
(IDYA) Investment Analysis - news.stocktradersdaily.com
FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald - Defense World
Stifel Financial Corp Sells 3,834 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Dimensional Fund Advisors LP Has $8.91 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc. - Defense World
Brokers Issue Forecasts for IDYA Q2 Earnings - Defense World
Leerink Partnrs Has Bullish Estimate for IDYA Q2 Earnings - Defense World
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer - Barchart.com
Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus
IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 10.2% After Earnings Miss - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Mariner LLC - Defense World
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors - marketscreener.com
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a - GuruFocus
Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus
Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus
IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com
FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa
FDA clears IDEAYA’s Phase 1 trial for new cancer drug - Investing.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - marketscreener.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors – Company Announcement - Financial Times
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
IDEAYA Biosciences (IDYA) to Release Quarterly Earnings on Tuesday - Defense World
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):